The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Targeting RNA to lower triglycerides: long strides from short molecules
Open accessAbstract
This editorial refers to ‘N-Acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides, and atherogenic lipoprotein levels’†, by V.J. Alexander et al., on page 2785. Despite remarkable progress in the prevention of atherothrombosis through lowering of LDL cholesterol (LDL-C), considerable cardiovascular risk remains. Triglycerides have gained renewed recognition as a marker of residual risk in patients with atherosclerotic cardiovascular disease (ASCVD) and in those with cardiometabolic risk factors.1 Several studies have shown an independent association of elevated triglycerides with an increased risk of cardiovascular events, even among patients with low LDL-C (<1.8 mmol/L or <70 mg/dL) treated with high-intensity statin therapy.2 Furthermore, recent genome-wide association studies and Mendelian randomization analyses support a causal role for triglyceride-rich lipoproteins (TRLs) in events due to coronary artery disease (CAD).3–5 For example, carriers of mutations that result in lifetime low levels of triglycerides have reduced risk of CAD. These observations support targeting triglycerides for reduction of cardiovascular risk. The recent Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT) furnished further support for the ‘triglyceride-lowering hypothesis’.6 In REDUCE-IT, 8179 patients with established cardiovascular disease, or with risk factors, elevated triglycerides (>1.5 mmol/L or >135 mg/dL), and optimal LDL-C (1.0–2.6 mmol/L or 40–100 mg/dL) on background statin therapy randomly received 2 g twice daily of icosapent ethyl, a highly purified ethyl ester of eicosapentaenoic acid that lowers triglycerides, or placebo. Relative to placebo, icosapent ethyl decreased triglycerides by ∼20%, the risk of ischaemic events including cardiovascular death by 25%, and total ischaemic events by 30% during the median follow-up of 4.9 years.7 , 8 Lowering of triglycerides probably contributed to the substantial benefit of icosapent ethyl in reducing ischaemic events in REDUCE-IT, in addition to other effects on prevention of atherothrombosis. Notably, most randomized clinical trials of drugs that lower triglycerides (i.e. fibrates, niacin, and omega-3 fatty acids except icosapent ethyl 4 g/day) have not shown reduction in cardiovascular events in statin-treated patients.1 Thus, despite the increased cardiovascular risk associated with triglycerides >1.1 mmol/L (>100 mg/dL), current guidelines only recommend pharmacological treatment for elevated triglycerides for severe hypertriglyceridaemia to prevent pancreatitis.9 , 10 Advancements in human genetics over the last decade have broadened our understanding of mechanisms of association of triglycerides with CAD.11 These developments have resulted in the discovery of novel pathways that regulate triglyceride levels, including apolipoprotein C3 (APOC3), angiopoietin-like 3, and angiopoietin-like 4, proteins currently under evaluation to lower triglycerides and reduce cardiovascular risk.11 APOC3 is a small apolipoprotein (79 amino acids) encoded by the APOC3 gene. Produced predominantly in the liver, APOC3 circulates attached to atherogenic TRLs such as very-low-density lipoprotein (VLDL), chylomicrons, and remnant cholesterol (Figure 1).12 Several studies have identified APOC3 as a key regulator of TRL metabolism. APOC3 increases levels of triglycerides by inhibiting the catabolism of TRLs by lipoprotein lipase and hepatic lipase, and by delaying remnant TRL clearance.11 , 12 Recent studies have associated loss-of-function variants in the APOC3 gene with decreased levels of APOC3, low triglycerides, and reduced risk of CAD.3 , 4 Elevated APOC3 levels are associated with an increased level of triglycerides, VLDLs, chylomicrons, remnant cholesterol, inflammation, and higher cardiovascular risk.13 Therefore, evidence thus far points to reduction of APOC3 as a promising therapeutic approach to lower triglycerides and reduce cardiovascular risk. To this end, an antisense oligonucleotide developed to target APOC3 mRNA lowers triglycerides by reducing APOC3 protein synthesis in the liver. As explained below, the advent of a selective strategy for targeting the liver in late-generation antisense oligonucleotides has markedly lowered the doses required to block the synthesis of proteins produced in hepatocytes and thus offers considerably improved tolerability of these agents. Relationship of APOC3 with triglycerides and coronary heart disease risk and the favourable cardiometabolic effects of APOC3 mRNA inhibition with an APOC3 antisense oligonucleotide. ApoB, apolipoprotein B; APOC3, apolipoprotein C3; ASO, antisense oligonucleotide; CHD, coronary heart disease; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; VLDL-C, very-low-density lipoprotein cholesterol. Advances in genetic technology have enabled targeting of disease-associated mRNAs.14 Antisense oligonucleotides consist of nucleotides complementary to the mRNA encod
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Volanesorsen (Waylivra; ISIS 304801 or IONIS-APOCIIIRx; Ionis/Akcea), a subcutaneously injected second-generation 2'-O-methoxyethyl chimeric antisense inhibitor, impairs translation of apolipoprotein (apo) C-III mRNA.58,67”
From Clinical review on triglycerides (2020) · cites this paper as [67]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317
Self-citation2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000624 · Cited by 907
Ference, B. A., Kastelein, J. J. P., Ray, K. K., Ginsberg, H. N., Chapman, M. J., Packard, C. J., Laufs, U., Oliver-Williams, C., Wood, A. M., Butterworth, A. S., et al. (2019) · JAMA · doi:10.1001/jama.2018.20045 · Cited by 703
Self-citationMiller, M., Cannon, C. P., Murphy, S. A., Qin, J., Ray, K. K., & Braunwald, E. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.10.038 · Cited by 610
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R. S., Hughes, S. G., Viney, N. J., Graham, M. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1400283 · Cited by 528 · cited 1×
“APOC3 mRNA in patients with hypertriglyceridaemia including those with extremely high triglycerides.(16,17) Prior APOC3 antisense oligonucleotide therapy did not lower apoB as seen in the present”
Background
Cited by
Clinical review on triglycerides
Laufs, U., Parhofer, K. G., Ginsberg, H. N., & Hegele, R. A. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz785 · Cited by 544
Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid
Mason, R. P., Libby, P., & Bhatt, D. L. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.313286 · Cited by 407
Self-citationThe dawn of a new era of targeted lipid-lowering therapies
Tokgözoğlu, L., & Libby, P. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab841 · Cited by 171
Self-citationLipid Lowering Drugs: Present Status and Future Developments
Ruscica, M., Ferri, N., Santos, R. D., Sirtori, C. R., & Corsini, A. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00918-3 · Cited by 73
Metadata
- Authors
- Qamar, A., Libby, P., & Bhatt, D. L.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Bhatt, Deepak L
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-05-15
- Volume
- 40
- Issue
- 33
- Pages
- 2797-2800
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- PMC
- PMC6735893
- OpenAlex
- W2945876616
- Cited by
- 14
- References
- 19
- Citations by year
- 2026: 2 · 2024: 2 · 2023: 2 · 2022: 1 · 2021: 3 · 2020: 2 · 2019: 2
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- European Heart Journal (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- NHLBI T32 (T32HL007604)
- American Heart Association Strategically Focused Research Network in Vascular Disease grant (18SFRN3390085, 18SFRN33960262)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- triglyceride lowering, triglyceride-rich lipoproteins, atherothrombosis, cardiovascular risk, icosapent ethyl, REDUCE-IT trial, omega-3 fatty acids, residual cardiovascular risk, atherosclerotic cardiovascular disease, LDL cholesterol
- MeSH terms
- Galactosamine, Lipoproteins, RNA, RNA, Messenger, Triglycerides, Apolipoprotein C-III
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting RNA to lower triglycerides: long strides from short molecules. https://app.cochat.ai/papers/10.1093/eurheartj/ehz321
- The paper
- Qamar, A., Libby, P., & Bhatt, D. L. (2019). Targeting RNA to lower triglycerides: long strides from short molecules. European Heart Journal. https://doi.org/10.1093/eurheartj/ehz321
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.